

CONDICIONAMENTO ISQUÉMICO CARDÍACO REMOTO: MECANISMOS DE CARDIOPROTECÇÃO E APLICAÇÕES CLÍNICAS

António Gaspar, Adelino F. Leite-Moreira

Departamentos de Fisiologia e Cirurgia Cardio-Torácica, Unidade de Investigação e Desenvolvimento Cardiovascular da Faculdade de Medicina da Universidade do Porto e Hospital de S. João e Departamento de Cardiologia do Hospital de Braga

Resumo

Apesar de uma melhoria significativa dos cuidados prestados no âmbito da doença coronária aguda, a mortalidade e morbidade associadas a esta última continuam significativas. Uma das explicações para esta ainda elevada mortalidade reside no facto de que a própria reperfusão coronária pode paradoxalmente provocar lesão miocárdica adicional, através da denominada lesão de isquemia-reperfusão, comprometendo assim, pelo menos parcialmente, o efeito benéfico da reperfusão miocárdica.

Ao longo das últimas duas décadas, várias intervenções farmacológicas (como o uso de antioxidantes, anti-inflamatórios, magnésio, glicose/insulina/potássio ou a rápida normalização do pH) foram estudadas com o intuito de prevenir a lesão de isquemia-reperfusão. Apesar dos resultados promissores obtidos com a experimentação animal, as tentativas de transposição desses resultados para o ser humano e consequentemente para a prática clínica têm sido desapontadoras.

Por outro lado, o condicionamento isquémico cardíaco é uma intervenção que tem produzido resultados positivos. De forma genérica, o conceito de "condicionamento isquémico" remete para a protecção induzida por curtos períodos de isquemia intercalados por períodos de reperfusão, previamente a um evento isquémico major. Os estímulos isquémicos podem ser aplicados antes (pré-condicionamento), durante (per-condicionamento) ou após (pós-condicionamento) o evento isquémico.

Uma descoberta importante no âmbito da investigação sobre condicionamento isquémico cardíaco, foi a de que a protecção podia ser induzida à distância, introduzindo o conceito de condicionamento isquémico remoto.

No presente trabalho, propusemo-nos rever os mecanismos subjacentes ao condicionamento isquémico cardíaco remoto e abordar as suas aplicações clínicas, considerando mais especificamente o pré- e o per-condicionamento.

Summary

Remote cardiac ischemic conditioning: Underlying mechanisms and clinical applications

Despite a significant improvement in the care of acute coronary disease, mortality and morbidity remain important. One explanation for this lies in the fact that the very coronary reperfusion may paradoxically result in additional myocardial injury, through the so-called ischemia-reperfusion injury, partially mitigating the beneficial effects of myocardial reperfusion.

Over the past two decades, numerous pharmacological interventions (such as the use of antioxidants, anti-inflammatory, magnesium, glucose/insulin/potassium, rapid normalization of pH) were studied in order to prevent ischemia-reperfusion injury. Despite the promising results obtained in animal experiments, attempts to transpose these results to humans, and consequently to clinical practice, have been disappointing.

On the other hand, cardiac ischemic conditioning is an intervention that has produced positive results. Ischemic conditioning refers to the protection induced by short periods of ischemia followed by reperfusion, prior to a major ischemic event. Ischemic stimulus can be applied before (pre-conditioning), during (per-conditioning) or after (post-conditioning) the major ischemic event.

An important finding regarding cardiac ischemic conditioning, was that protection could be induced remotely, introducing the concept of remote ischemic conditioning.

In this paper, we proposed to review the mechanisms underlying remote ischemic cardiac conditioning and the possible clinical applications, considering more specifically pre and per-conditioning

INTRODUCTION

Coronary heart disease is one of the leading causes of mortality worldwide, accounting for more than 7 million deaths per year (about 12.8% of all deaths)¹. It is estimated that in Europe every sixth man and every seventh woman will die of acute myocardial infarction (AMI)².

However, recent studies and registries have showed a reduction in AMI mortality following the increased use of reperfusion therapy (mainly with percutaneous coronary intervention), newer antithrombotic therapies, and adherence to secondary prevention measures (pharmacological treatment and changes in lifestyle)³⁻⁶. In the context of AMI with ST segment elevation, rapid restoration of coronary flow is actually the most effective strategy for reducing the infarct size and thus improving prognosis associated with AMI.

Thus, despite a significant improvement in the care of acute coronary disease, mortality and morbidity associated with the latter remain high.

One of the reasons for a mortality rate still so high is that reperfusion itself can paradoxically cause additional myocardial injury, through the so-called ischemia-reperfusion injury (or reperfusion injury), reducing the beneficial effects of myocardial reperfusion⁷⁻⁹. Ischemia-reperfusion injury (IRI) has classically been described as causing four main types of cardiac dysfunction: myocardial stunning, the phenomenon of "no-reflow", reperfusion arrhythmia and myocardial necrosis (called "lethal reperfusion injury")⁹⁻¹². IRI may account for up to 40 - 50% of the final infarct size, thereby contributing to an increased mortality and progression to heart failure (Fig. 1)⁹. Several factors have been suggested as contributing to IRI: oxidative stress, changes in pH, calcium overload and acute inflammatory response. These events favour the opening of




Figure 1

Schematic representation of the contribution of ischemia-reperfusion injury to the final size of myocardial infarction.

the mitochondrial permeability transition pore (mPTP). The mPTP is a non-specific channel located in the inner membrane of the mitochondria whose opening leads ultimately to cell lysis^{8, 9, 13-16}. The mPTP is thus a critical determinant of IRI.

Over the past three decades, several pharmacological interventions (use of antioxidants, anti-inflammatory agents, magnesium, glucose/insulin/potassium or rapid normalization of pH) were studied in order to prevent IRI. Despite promising results in animal experiments, attempts to translate those results into humans have been largely disappointing^{9,17,18}.

On the opposite, cardiac ischemic conditioning is an intervention that has produced positive results, both in animal experiments and in human clinical trials¹⁷⁻²⁷.

The concept of "ischemic conditioning" refers to the protection induced by short cycles of ischemia and reperfusion prior to a major ischemic event. Various studies have shown that ischemic conditioning is ubiquitous and can be applied in all organs.

Murry et al. first described cardiac ischemic conditioning in a canine model in 1986²⁸⁻²⁹. These authors observed that the application of four 5-minutes cycles of myocardial ischemia (by occlusion of a coronary artery) alternating with 5-minutes of reperfusion could protect the myocardium against a longer period of ischemia. In subsequent years, ischemic conditioning was the subject of intense investigation, both in the description of the underlying cellular mechanisms and the assessment of its effectiveness in various clinical settings¹⁷⁻²⁷.

Due to the extensive research conducted in the last 25 years, we now know that stimuli may be applied before ischemia (preconditioning - as originally described by Murry et al.), during (per-conditioning) or after (post-conditioning) the major ischemic event, thereby allowing three windows for the application of this therapeutic intervention.

An important discovery about cardiac conditioning was the existence of two windows of cardioprotection. After the initial ischemic stimulus, the protection induced immediately, called "classic ischemic preconditioning", extends over a maximum period of about 1 to 2 hours. Notably, 12 to 24 hours after the initial ischemic stimulus, a second window appears, lasting for 48 to 72 hours, although resulting in a lesser amount of protection³⁰.

Another remarkable finding about cardiac ischemic conditioning was that cardioprotection could be induced at a distance, introducing the concept of remote cardiac ischemic conditioning.

DEFINITION

Remote cardiac ischemic conditioning (RCIC) describes the cardioprotection induced by short cycles of ischemia and reperfusion applied to a distant organ before, during or even after a prolonged period of myocardial ischemia.

Przyklenk et al. first described the concept of RCIC (as preconditioning) in 1993³¹. These authors demonstrated, in a canine model, that the application of transient ischemia to the circumflex coronary artery territory lessened the effects

of a potentially lethal ischemia subsequently applied to the territory supplied by the anterior descending coronary artery.

Later, in 2002, Kharbanda et al. demonstrated that RCIC could be reproduced non-invasively by applying short periods of ischemia and reperfusion in the forearm, using a blood pressure cuff³². Since then, several studies have highlighted the benefits of RCIC in different clinical circumstances²⁵⁻²⁷.

MECHANISMS

Although the mechanisms underlying the immediate cardioprotection of RCIC are not fully understood, studies have shown that some of the signalling pathways activated in cardiomyocytes preconditioned at a distance appear to be similar to the ones recruited in preconditioning and post-conditioning applied directly to the heart³³⁻³⁶.

However, it is the mechanism linking the remote organ to the heart that is less clear and which constitutes the main difference between the direct and the remote ischemic conditioning³⁵.

1. Communication between the remote organ and the heart

Three main hypotheses, each one favouring a different pathway, were proposed to explain the transmission of a protective signal from the remote organ to the heart.

a. Humoral pathway

The observation that a period of reperfusion of the organ submitted to briefs periods of ischemia was necessary for remote cardioprotection to occur, soon raised the suspicion that reperfusion was required to carry a substance previously produced by ischemic preconditioning³⁷⁻³⁸. Later, several studies added arguments to this hypothesis. One study revealed the occurrence of cardioprotection in a rabbit receiving blood from another rabbit previously submitted to local and remote cardiac preconditioning³⁹. Another study showed that a pig, receiving a denervated heart and subsequently subjected to ischemia of a limb, continued to benefit from cardioprotection, reinforcing the hypothesis of a humoral factor mediating the cardioprotection⁴⁰.

Some of the substances identified as possible humoral factor are opioids, endocannabinoids and adenosine⁴¹⁻⁴⁴.

b. Neuronal pathway

When considering the neuronal pathway hypothesis, it was proposed that afferent nerve fibres of the remote organ were activated by endogenous substances produced by the ischemic stimulus, with subsequent activation of efferent nerve fibres in the heart. The substances most often involved in the activation of afferent nerve fibres are adenosine, bradykinin and the neurotransmitter CGRP ("calcitonin gene-related peptide")⁴⁵⁻⁴⁸.

Several studies have pointed the existence of a neuronal pathway for the transmission of the cardioprotective signal and assessed possible candidates for the initial activation of the afferent nerve fibres. In general, the various

studies followed a similar methodology: the role of the nervous system in the signal transmission of cardioprotection was shown by demonstrating its inhibition following the destruction of afferent nerve fibres in the remote organ submitted to the initial ischemic stimulus⁴⁵⁻⁴⁸.

c. Systemic pathway

RCIC has been shown to suppress the inflammatory response and induce a favourable profile of gene transcription in the myocardium, promoting anti-inflammatory and anti-apoptotic responses^{49,50}. The understanding of the exact

contribution of such responses in the cardioprotection induced by RCIC requires further investigation.

It should be noted that the pathways described above are likely not mutually exclusive but rather interact with each other.

2. Mechanisms involved in myocardial cardioprotection elicited by remote conditioning

After the cardioprotective signal has been transmitted from the remote organ to the heart, intracellular mechanisms of signal transduction are recruited to mediate




Figure 2

Mechanisms underlying cardiac remote ischemic conditioning. CGRP: calcitonin gene-related peptide; Erk 1/2: extracellular signal-regulated kinases; JNK: Jun N-terminal kinase; K_{ATP} channel: ATP-dependent mitochondrial potassium channel; MAPK: mitogen-activated protein kinases; mPTP: mitochondrial permeability transition pore; NO: nitric oxide; RISK: reperfusion injury salvage kinase; SAFE: survivor activating factor enhancement; "+": stimulation / activation.

cardioprotection. At this point, the mechanisms are similar to the ones underlying ischemic pre and post-conditioning applied directly to the heart^{34-36, 51-52}.

The first step is the activation of G protein coupled receptors by ligands as adenosine, bradykinin, angiotensin I, opioids and endocannabinoids^{41,44,45,53}. The activation of these receptors will in turn lead to the activation of intracellular protein kinases such as protein kinase G, protein kinase C (especially its isoform ϵ), protein kinases Akt and Erk 1/2 (kinases of the protective RISK pathway - "reperfusion injury salvage kinase") or generation of intracellular signalling molecules such as nitric oxide (NO) or reactive oxygen species^{45,54-57}. Another pathway that may also mediate cardioprotection in RCIC, as in classical pre-conditioning, is the SAFE pathway ("survivor activating factor enhancement") that involves the activation of STAT1/3 ("signal transducer and activator of transcription") by TNF α , conferring cardioprotection through induction of anti-apoptotic genes and inhibition of pro-apoptotic ones⁵⁸.

The final target of the various intracellular mechanisms seems to be the mitochondria via the activation of the mitochondrial ATP-dependent potassium channel (K_{ATP} channel) and, ultimately, the inhibition of the opening of the mitochondrial permeability transition pore (mPTP)^{51,59-62}. As mentioned above, the mPTP is a non-specific channel located in the inner membrane of the mitochondria. Its opening leads to an equilibrium of H⁺ ions on each side of the membrane with the consequent loss of the membrane potential necessary for ATP production. The mPTP also allows the entry of water into the mitochondria, causing its dilation and ultimately cell lysis. The opening of the mPTP is favoured by increased intracellular concentration of Ca²⁺, inorganic phosphate and reactive oxygen species, which occurs after reperfusion⁹. The various intracellular signalling pathways mentioned previously inhibit mPTP opening, preventing the cascade of events leading to the death of the myocyte^{51,59-61}.

3. DELAYED CARDIOPROTECTION OR SECOND WINDOW OF PROTECTION

As in cardiac conditioning induced locally, RCIC seems to induce two windows of protection, one immediate and one delayed^{33,62}.

The mechanisms underlying the delayed response are very similar to those described for the immediate response: communication between the remote organ and the heart, triggers recruiting mediators which in turn lead to the activation of the effector of cardioprotection (most probably the mPTP)⁶².

The main difference between the delayed and immediate responses lies in the recruitment of early mediators (protein kinase C, protein tyrosine kinase, MEK 1/2-Erk 1/2,...), which activate transcription factors (STAT 1/3, NF κ B ("nuclear factor kappa-light-chain enhancer of activated B-cells"), AP-1 ("activator-protein-1"), Nrf2 ("nuclear factor-like 2"),...). These transcription factors induce the synthesis of distal mediators 12 to 24 hours later (inducible NO synthase, heat shock proteins, cyclooxygenase 2). These mediators finally recruit the final effectors of cardioprotection

(mitochondrial K_{ATP} channel and mPTP)⁶².

The intermediate steps described above explain the observed delay of 12 to 24 hours until the beginning of the second window of protection.

The proposed mechanisms underlying RCIC are summarized in Fig. 2.

CLINICAL APPLICATIONS

When we considered the ischemic preconditioning, the need to apply the stimulus prior to the ischemic heart injury limits its application to situations in which myocardial injury is predictable. Thus, the ideal context for the application of ischemic preconditioning of the heart is elective interventions associated with myocardial injury such as cardiac surgery and percutaneous coronary angioplasty.

On the other hand, ischemic per-conditioning begun to be studied in the last 5 years, as an adjunct to angioplasty in the context of AMI with ST segment elevation.

1. Cardiac surgery

Perioperative myocardial injury after cardiac surgery (evidenced by the elevation of biomarkers of myocardial necrosis such as troponin I or T) is associated with worse prognosis. As a result, the prevention of the former is of great importance⁶³⁻⁶⁶.

Cardiac surgery for the correction of congenital defects in children was the first clinical setting in which remote cardiac ischemic pre-conditioning (RCIPreC) has been studied²³. In the study by Cheung and co-workers, a protocol of remote ischemic preconditioning (four 5-minute cycles of inflation and deflation of a blood pressure cuff applied to the thigh) allowed the reduction of perioperative myocardial injury (demonstrated by the lower elevation of troponin I), need for inotropic support and airway resistance²³.

In the context of coronary artery bypass surgery (CABG) in adults, Hausenloy et al. were the first to demonstrate that RCIPreC (induced by three 5-minute cycles of inflation and deflation of a blood pressure cuff applied to the arm) could lead to a reduction of perioperative myocardial injury²⁴. Subsequently, several studies have confirmed the cardioprotective effect of RCIPreC in CABG surgery⁶⁷⁻⁶⁸.

However, one of the biggest studies performed afterward in the setting of CABG showed negative results, failing to demonstrate beneficial effects of a remote ischemic preconditioning protocol (three 5-minute cycles of inflation and deflation of a blood pressure cuff applied to the arm). Some hypotheses have been evoked to explain the negative results of this study: the inclusion of patients with recurrent angina (unintentionally preconditioned), nitrate use, the anesthetic protocol and inefficiency of remote ischemic preconditioning protocol⁶⁹.

Two large trials (ERICCA and RIPHeart), with samples large enough to demonstrate possible benefits of RCIPreC in regard to hard clinical events, are currently under recruitment. These studies will bring more definitive answers regarding the clinical utility of RCIPreC in the setting of CABG.

2. Elective percutaneous coronary angioplasty

As shown for cardiac surgery, the occurrence of myocardial injury in the setting of elective percutaneous coronary intervention (PCI) is associated with worse prognosis, making necessary the utilization of effective strategies for its prevention⁷⁰⁻⁷³.

The first clinical study evaluating RCIPreC for elective PCI did not show any benefit, possibly due to an inadequate remote ischemic conditioning protocol⁷⁴. However, in a subsequent study conducted by Hoole et al. (CRISP trial), a protocol of remote ischemic preconditioning (three 5-minute cycles of inflation and deflation of a blood pressure cuff applied to the arm) resulted in a lower troponin T elevation after the procedure²⁵. Interestingly, the same authors did not demonstrate benefits of RCIPreC in reducing myocardial dysfunction in patients with coronary heart disease submitted to dobutamine stress echocardiography⁷⁵.

We are currently missing large-scale trials to evaluate a possible impact on the prevention of adverse clinical events.

3. Acute myocardial infarction with ST-segment elevation

Despite intense investigation on cardiac ischemic conditioning for over two decades, only recently protocols of remote ischemic conditioning have been tested in the setting of AMI with ST segment elevation²⁶⁻²⁷.

In 2010, Rentoukas et al. were the first to present the results of a randomized trial testing the effect of a protocol of remote cardiac ischemic per-conditioning (RCIPerC), with or without morphine, in the setting of AMI with ST-segment elevation. In this study, 96 patients were randomized into 3 groups: RCIPerC (three cycles of 4-minute inflations and deflations of a blood pressure cuff placed on the upper arm; inflation to 20 mmHg above systolic pressure and deflation to 0 mmHg), RCIPer with morphine (administered prior to per-conditioning) or control treatment (three cycles of 4-minute inflation to 20 mmHg below diastolic blood pressure of a blood pressure cuff placed on the upper arm and deflation to 0 mmHg). Overall, a complete resolution of ST elevation was achieved more often in patients receiving any form of RCIPerC. The group that received RCIPerC with morphine had a greater reduction in ST elevation and lowest elevation of troponin I in relation to the control group while the patients undergoing RCIPerC alone had a non significant trend for greater reduction of ST elevation and lower elevation of troponin I²⁶.

In 2010, Botker et al. published the results of the largest randomized study conducted so far to evaluate the effects of RCIPerC in the setting of AMI with ST-segment elevation. In this study, 333 patients were randomized to RCIPerC (four 5-minute cycles of inflation to 200 mmHg and deflation to 0 mmHg of a blood pressure cuff applied to the arm) or control treatment (deflated cuff placed on the arm). Although only 142 of the 333 patients initially randomized were analysed, a higher rate of myocardial salvage was observed among patients undergoing RCIPerC (0.75 vs. 0.55, $p = 0.0333$). The authors also showed that the beneficial effects of RCIPerC were more pronounced in patients

presenting with more extensive EAM, particularly those related to the occlusion of the left anterior descending.

Studies of larger scale are needed for assessing the effect of RCIPerC on the incidence of more relevant clinical adverse events.

CONCLUSION

The mortality associated with coronary heart disease has been declining in recent years as a result of the greater use of revascularization (both percutaneous and surgical) and the improvement of antithrombotic treatment. However, the in-hospital mortality recorded in European countries remains high, ranging between 6 and 14%². One factor that may contribute to this still significant mortality is the IRI. The IRI may contribute to up to 40 to 50% of the final infarct size, thereby facilitating the development of heart failure with the significant mortality and morbidity associated to it⁹.

Remote ischemic conditioning is a safe, non-invasive and very low cost intervention with the potential to reduce the morbidity and mortality associated with coronary heart disease. Until now, extensive investigation has been conducted with positive results. In the past 5 years, several studies have evaluated the potential beneficial effects of RCIC in human, once again with encouraging results. However, we are lacking large-scale studies to verify the clinical impact of RCIC, namely for the reduction of clinically relevant adverse events. These studies may confirm RCIC as a clinically useful tool or confine it to laboratory studies.

ACKNOWLEDGEMENTS

Work funded by the Portuguese Foundation for Science and Technology (Projects PEst-C/SAU/UI0051/2011 and EXCL/BIM-MEC/0055/2012) through the Cardiovascular R&D Unit and by the European Commission Grant FP7-Health-2010 (MEDIA-261409).

Conflicts of interest: NONE.

REFERENCES

1. WHO - Health statistics and health information systems, updated May 2011, <http://www.who.int/evidence/bod>
2. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Steg G, James S, Dan A et al. *European Heart Journal* 2012;33:2569-2619.
3. Widimsky P, Wijns W, Fajadet J et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. *Eur Heart J* 2010;31:943-957.
4. McManus DD, Gore J, Yarzebski J et al. trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. *Am J Med* 2011;124:40-47.
5. Jernberg T, Johanson P, Held C et al. Association between

- adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. *J Am Med Assoc* 2011;305:1677-1684.
6. Fox KA, Steg PG, Eagle KA et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. *J Am Med Assoc* 2007;297:1892-1900.
 7. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? *J Clin Invest*. 1985 Nov;76(5):1713-9.
 8. Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. *Cardiovasc Res* 1998;38:291-300.
 9. Yellon D; Hausenloy D. Myocardial Reperfusion Injury. *N Engl J Med* 2007; 357:1121-1135
 10. Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. *Nat Clin Pract Cardiovasc Med* 2006;3:499-506.
 11. Manning AS, Hearse DJ. Reperfusion-induced arrhythmias: mechanisms and prevention. *J Mol Cell Cardiol* 1984;16:497-518.
 12. Bolli R, Marbán E. Molecular and cellular mechanisms of myocardial stunning. *Physiol Rev* 1999;79:609-34.
 13. Hearse DJ, Humphrey SM, Chain EB. Abrupt reoxygenation of the anoxic potassium arrested perfused rat heart: a study of myocardial enzyme release. *J Mol Cell Cardiol*. 1973;5(4):395-407.
 14. Lemasters JJ, Bond JM, Chacon E, et al. The pH paradox in ischaemia-reperfusion injury to cardiac myocytes. *EXS*. 1996; 76:99-114.
 15. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. *Cardiovasc Res*. 2004;61(3):481-497.
 16. Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. *Circ Res*. 2001;89(12):1191-1198.
 17. Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA. Myocardial protection at a crossroads: the need for translation into clinical therapy. *Circ Res* 2004;95:125-34.
 18. Dirksen MT, Laarman GJ, Simoons ML, Duncker DJGM. Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. *Cardiovasc Res* 2007;74:343-55.
 19. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. *Am J Physiol Heart Circ Physiol* 2003;285: H579-H588. [Erratum, *Am J Physiol Heart Circ Physiol* 2004;286:H477.]
 20. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. *Circulation* 2005;112:2143-8.
 21. Laskey WK. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: a pilot study. *Catheter Cardiovasc Interv* 2005;65:361-7.
 22. Ma X, Zhang X, Li C, Luo M. Effect of postconditioning on coronary blood flow velocity and endothelial function and LV recovery after myocardial infarction. *J Interv Cardiol* 2006;19:367-75.
 23. Cheung MM, Kharbanda RK, Konstantinov IE, et al. Randomised controlled trial of the effects of remote ischaemic preconditioning on children undergoing cardiac surgery: first clinical application in humans. *J Am Coll Cardiol*. 2006; 47(11):2277-2282.
 24. Hausenloy DJ, Mwamure PK, Venugopal V, et al. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomized controlled trial. *Lancet*. 2007;370(9587):575-579.
 25. Hoole SP, Heck PM, Sharples L, et al. Cardiac remote ischaemic preconditioning in coronary stenting (CRISP Stent) study: a prospective, randomised control trial. *Circulation*. 2009;119(6): 820-827.
 26. Rentoukas I, Giannopoulos G, Kaoukis A, et al. Cardioprotective role of remote ischaemic preconditioning in primary percutaneous coronary intervention: enhancement by opioid action. *JACC Cardiovasc Interv*. 2010;3(1):49-55.
 27. Bøtker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. *Lancet*. 2010; 375(9716):727-734.
 28. Reimer K, Murry C, Yamasawa I, Hill M, Jennings R. Four brief periods of ischaemia cause no cumulative ATP loss or necrosis. *Am J Physiol* 1986; 251: H1306-15.
 29. Murry C, Jennings R, Reimer K. Preconditioning with ischaemia: a delay of lethal cell injury in ischaemic myocardium. *Circulation* 1986; 74:1124-36.
 30. Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. *Circulation*. 1993;88(3):1264-1272.
 31. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischaemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. *Circulation*. 1993;87(3):893-899.
 32. Kharbanda RK, Mortensen UM, White PA, et al. Transient limb ischemia induces remote ischemic preconditioning in vivo. *Circulation*. 2002;106(23):2881-2883.
 33. Loukogeorgakis SP, Panagiotidou AT, Broadhead MW, Donald A, Deanfield JE, MacAllister RJ. Remote ischemic preconditioning provides early and late protection against endothelial ischemia-reperfusion injury in humans: role of the autonomic nervous system. *J Am Coll Cardiol* 2005;46:450-456.
 34. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: united at reperfusion. *Pharmacol Ther* 2007;116:173-191.
 35. Hausenloy D and Yellon D. Remote ischaemic preconditioning: underlying mechanisms and clinical application. *Cardiovascular Research* (2008) 79, 377-386
 36. Hausenloy D, Yellon D. Preconditioning and postconditioning: underlying mechanisms and clinical application. *Atherosclerosis*. 2009 Jun;204(2):334-41.
 37. McClanahan T, Nao B, Wolke L, Martin BJ, Mezt TE. Brief renal occlusion and reperfusion reduces myocardial infarct size in rabbits. (Abstract). *FASEB J* 1993;7:A18.
 38. Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD. Myocardial protection by brief ischemia in noncardiac tissue. *Circulation* 1996;94:2193-2200.
 39. Dickson EW, Reinhardt CP, Renzi FP, Becker RC, Porcaro WA, Heard SO. Ischemic preconditioning may be transferable via whole blood transfusion: preliminary evidence. *J Thromb Thrombolysis* 1999;8:123-129.
 40. Konstantinov IE, Li J, Cheung MM, Shimizu M, Stokoe J, Kharbanda RK et al. Remote ischemic preconditioning of the recipient reduces myocardial ischemia-reperfusion injury of the denervated donor heart via a Katp channel-dependent mechanism. *Transplantation* 2005;79:1691-1695.
 41. Patel HH, Moore J, Hsu AK, Gross GJ. Cardioprotection at a distance: mesenteric artery occlusion protects the myocardium via an opioid sensitive mechanism. *J Mol Cell Cardiol* 2002;34:1317-1323.
 42. Dickson EW, Tubbs RJ, Porcaro WA, Lee WJ, Blehar DJ, Carraway RE et al. Myocardial preconditioning factors evoke mesenteric ischemic tolerance via opioid receptors and K(ATP) channels. *Am J Physiol Heart Circ Physiol* 2002;283:H22-H28.
 43. Hajrasouliha AR, Tavakoli S, Ghasemi M, Jabehdar-Maralani P, Sadeghipour H, Ebrahimi F et al. Endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid CB(2) receptors in the rat heart. *Eur J Pharmacol* 2008;579:246-52.
 44. Liem DA, Verdouw PD, Ploeg H, Kazim S, Duncker DJ. Sites of action of adenosine in interorgan preconditioning of the heart. *Am J Physiol Heart Circ Physiol* 2002;283:H29-H37.
 45. Pell TJ, Baxter GF, Yellon DM, Drew GM. Renal ischemia preconditioning myocardium: role of adenosine receptors and ATP-sensitive

- potassium channels. *Am J Physiol* 1998;275:H1542–H1547.
46. Schoemaker RG, van Heijningen CL. Bradykinin mediates cardiac preconditioning at a distance. *Am J Physiol Heart Circ Physiol* 2000;278: H1571–H1576.
 47. Tang ZL, Dai W, Li YJ, Deng HW. Involvement of capsaicin-sensitive sensory nerves in early and delayed cardioprotection induced by a brief ischaemia of the small intestine. *Naunyn Schmiedebergs Arch Pharmacol* 1999;359:243–247.
 48. Liem DA, Verdouw PD, Ploeg H, Kazim S, Duncker DJ. Sites of action of adenosine in interorgan preconditioning of the heart. *Am J Physiol Heart Circ Physiol* 2002;283:H29–H37.
 49. Konstantinov IE, Arab S, Kharbanda RK, Li J, Cheung MM, Chepepanov V et al. The remote ischemic preconditioning stimulus modifies inflammatory gene expression in humans. *Physiol Genomics* 2004;19:143–150.
 50. Peralta C, Fernandez L, Panes J, Prats N, Sans M, Pique JM et al. Preconditioning protects against systemic disorders associated with hepatic ischemia-reperfusion through blockade of tumor necrosis factor-induced P-selectin up-regulation in the rat. *Hepatology* 2001;33:100–113.
 51. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. *Physiol Rev* 2003;83:1113–1151.
 52. Vinten-Johansen J. Postconditioning: a mechanical maneuver that triggers biological and molecular cardioprotective responses to reperfusion. *Heart Fail Rev* 2007;12:235–244.
 53. Singh D, Chopra K. Evidence of the role of angiotensin AT(1) receptors in remote renal preconditioning of myocardium. *Methods Find Exp Clin Pharmacol* 2004;26:117–122.
 54. Wolfrum S, Schneider K, Heidebreder M, Nienstedt J, Dominiak P, Dendorfer A. Remote preconditioning protects the heart by activating myocardial PKCepsilon-isoform. *Cardiovasc Res* 2002;55:583–589.
 55. Weinbrenner C, Nelles M, Herzog N, Sarvary L, Strasser RH. Remote preconditioning by infrarenal occlusion of the aorta protects the heart from infarction: a newly identified non-neuronal but PKC-dependent pathway. *Cardiovasc Res* 2002;55:590–601.
 56. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. *Heart Fail Rev* 2007;12:217–34.
 57. D. J. Hausenloy and D. M. Yellon, "New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)- pathway," *Cardiovascular Research*, vol. 61, no. 3, pp. 448–460, 2004.
 58. S. Lecour, "Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway?" *Journal of Molecular and Cellular Cardiology*, vol. 47, no. 1, pp. 32–40, 2009.
 59. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? *Cardiovasc Res* 2002;55:534–43.
 60. Downey JM, Davis AM, Cohen MV. Signaling pathways in ischemic preconditioning. *Heart Fail Rev* 2007;12:181–8.
 61. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. *J Mol Cell Cardiol* 2003;35:339–341.
 62. Hausenloy D and Yellon D. The Second Window of Preconditioning (SWOP) Where Are We Now? *Cardiovasc Drugs Ther* (2010) 24:235–254.
 63. Kathiresan S, Servoss SJ, Newell JB, et al. Cardiac troponin T elevation after coronary artery bypass grafting is associated with increased one-year mortality. *Am J Cardiol*. 2004;94(7): 879-881.
 64. Mohammed AA, Agnihotri AK, van Kimmenade RR, et al. Prospective, comprehensive assessment of cardiac troponin T testing after coronary artery bypass graft surgery. *Circulation*. 2009; 120(10):843-850.
 65. Fellahi JL, Gue X, Richomme X, Monier E, Guillou L, Riou B. Short- and long-term prognostic value of postoperative cardiac troponin i concentration in patients undergoing coronary artery bypass grafting. *Anesthesiology*. 2003;99(2):270-274.
 66. Croal BL, Hillis GS, Gibson PH, et al. Relationship between postoperative cardiac troponin I levels and outcome of cardiac surgery. *Circulation*. 2006;114(14):1468-1475.
 67. Venugopal V, Hausenloy DJ, Ludman A, et al. Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold-blood cardioplegia: a randomised controlled trial. *Heart*. 2009;95(19):1567-1571.
 68. Thielmann M, Kottenberg E, Boengler K, et al. Remote ischaemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. *Basic Res Cardiol*. 2010;105(5):657-664.
 69. Luciano C, Hausenloy D, Yellon D. Remote Ischemic Conditioning: A Clinical Trial's Update. *Journal of Cardiovascular Pharmacology and Therapeutics* 16(3-4) 304-312.
 70. Nageh T, Sherwood RA, Harris BM, Thomas MR. Prognostic role of cardiac troponin i after percutaneous coronary intervention in stable coronary disease. *Heart*. 2005;91(9):1181-1185.
 71. Kizer JR, Muttrej MR, Matthai WH, et al. Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention. *Eur Heart J*. 2003;24(14):1314-1322.
 72. Ricciardi MJ, Davidson CJ, Gubernikoff G, et al. Troponin I elevation and cardiac events after percutaneous coronary intervention. *Am Heart J*. 2003;145(3):522-528.
 73. Babu GG, Walker JM, Yellon DM, Hausenloy DJ. Periprocedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. *Eur Heart J*. 2011;32(1):23-32.
 74. Iliodromitis EK, Kyrzopoulos S, Paraskevidis IA, et al. Increased C reactive protein and cardiac enzyme levels after coronary stent implantation. is there protection by remote ischaemic preconditioning? *Heart*. 2006;92(12):1821-1826.
 75. Hoole SP, Khan SN, White PA, et al. Remote ischaemic preconditioning does not attenuate ischaemic left ventricular dysfunction in humans. *Eur J Heart Fail*. 2009;11(5):497-505.